Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Breast Cancer

  Free Subscription


Articles published in Lancet Oncol

Retrieve available abstracts of 206 articles:
HTML format



Single Articles


    July 2021
  1. DENKERT C, Seither F, Schneeweiss A, Link T, et al
    Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials.
    Lancet Oncol. 2021 Jul 9. pii: S1470-2045(21)00301.
    PubMed     Abstract available


    June 2021
  2. GANGULY S, Gogia A
    Pembrolizumab monotherapy in advanced triple-negative breast cancer.
    Lancet Oncol. 2021;22:e224.
    PubMed    


  3. AMANT F, Lefrere H, Borges VF, Cardonick E, et al
    The definition of pregnancy-associated breast cancer is outdated and should no longer be used.
    Lancet Oncol. 2021;22:753-754.
    PubMed    


  4. GRINDA T, Delaloge S
    BRCA2: a 25-year journey from gene identification to targeted cancer treatment.
    Lancet Oncol. 2021;22:763-764.
    PubMed    


    May 2021
  5. PEREZ-GARCIA JM, Gebhart G, Ruiz Borrego M, Stradella A, et al
    Chemotherapy de-escalation using an (18)F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial.
    Lancet Oncol. 2021 May 18. pii: S1470-2045(21)00122.
    PubMed     Abstract available


  6. BIGANZOLI L, Battisti NML, Wildiers H, McCartney A, et al
    Updated recommendations regarding the management of older patients with breast cancer: a joint paper from the European Society of Breast Cancer Specialists (EUSOMA) and the International Society of Geriatric Oncology (SIOG).
    Lancet Oncol. 2021 May 14. pii: S1470-2045(20)30741.
    PubMed     Abstract available


  7. BRAAT AJAT, Heerma van Voss MR, Bijlsma RM
    (99m)Tc-HDP bone scintigraphy confirming parathyroid hormone-related peptide paraneoplastic syndrome in metastatic breast cancer.
    Lancet Oncol. 2021;22:e216.
    PubMed    


    April 2021
  8. FRANZOI MA, Agostinetto E, Perachino M, Del Mastro L, et al
    Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancer.
    Lancet Oncol. 2021 Apr 20. pii: S1470-2045(20)30666.
    PubMed     Abstract available


  9. BUCHHOLZ TA
    Increasing the value of radiotherapy in breast cancer.
    Lancet Oncol. 2021 Apr 9. pii: S1470-2045(21)00120.
    PubMed    


  10. ORECCHIA R, Veronesi U, Maisonneuve P, Galimberti VE, et al
    Intraoperative irradiation for early breast cancer (ELIOT): long-term recurrence and survival outcomes from a single-centre, randomised, phase 3 equivalence trial.
    Lancet Oncol. 2021 Apr 9. pii: S1470-2045(21)00080.
    PubMed     Abstract available


  11. RUGO HS, Lerebours F, Ciruelos E, Drullinsky P, et al
    Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study.
    Lancet Oncol. 2021;22:489-498.
    PubMed     Abstract available


  12. HEIL J, Pfob A, Morrow M
    De-escalation of breast and axillary surgery in exceptional responders to neoadjuvant systemic treatment.
    Lancet Oncol. 2021;22:435-436.
    PubMed    


    March 2021
  13. PICCART M, van 't Veer LJ, Poncet C, Lopes Cardozo JMN, et al
    70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age.
    Lancet Oncol. 2021 Mar 12. pii: S1470-2045(21)00007.
    PubMed     Abstract available


  14. ANDERSON BO, Ilbawi AM, Fidarova E, Weiderpass E, et al
    The Global Breast Cancer Initiative: a strategic collaboration to strengthen health care for non-communicable diseases.
    Lancet Oncol. 2021 Mar 5. pii: S1470-2045(21)00071.
    PubMed    


  15. AMIR E, Cescon DW
    Pembrolizumab monotherapy in metastatic triple-negative breast cancer.
    Lancet Oncol. 2021 Mar 4. pii: S1470-2045(21)00019.
    PubMed    


  16. WINER EP, Lipatov O, Im SA, Goncalves A, et al
    Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial.
    Lancet Oncol. 2021 Mar 4. pii: S1470-2045(20)30754.
    PubMed     Abstract available


  17. CARRASCOSA MF, Fernandez-Ayala M, Cano Hoz M, Abascal Carrera I, et al
    Pathological fracture from clinically occult breast cancer.
    Lancet Oncol. 2021;22:e131.
    PubMed    


    February 2021
  18. XU B, Yan M, Ma F, Hu X, et al
    Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial.
    Lancet Oncol. 2021 Feb 11. pii: S1470-2045(20)30702.
    PubMed     Abstract available


  19. RYZHOV A, Corbex M, Pineros M, Barchuk A, et al
    Comparison of breast cancer and cervical cancer stage distributions in ten newly independent states of the former Soviet Union: a population-based study.
    Lancet Oncol. 2021 Feb 5. pii: S1470-2045(20)30674.
    PubMed     Abstract available


  20. VILLARREAL-GARZA C, Aranda-Gutierrez A, Ferrigno AS, Platas A, et al
    The challenges of breast cancer care in Mexico during health-care reforms and COVID-19.
    Lancet Oncol. 2021;22:170-171.
    PubMed    


  21. POORTMANS PM, Weltens C, Kirkove C
    Indications for individual internal mammary node irradiation - Authors' reply.
    Lancet Oncol. 2021;22:e41.
    PubMed    


  22. QIU PF, Wang XE, Wang YS
    Indications for individual internal mammary node irradiation.
    Lancet Oncol. 2021;22:e40.
    PubMed    


  23. WILLIAMSON L
    More women dismissing breast reconstruction after mastectomy.
    Lancet Oncol. 2021;22:e43.
    PubMed    


    January 2021
  24. MAYER EL, Dueck AC, Martin M, Rubovszky G, et al
    Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study.
    Lancet Oncol. 2021 Jan 15. pii: S1470-2045(20)30642.
    PubMed     Abstract available


  25. XU B, Fan Y
    CDK4/6 inhibition in early-stage breast cancer: how far is it from becoming standard of care?
    Lancet Oncol. 2021 Jan 15. pii: S1470-2045(20)30757.
    PubMed    


  26. MORGAN AJ, Giannoudis A, Palmieri C
    The genomic landscape of breast cancer brain metastases: a systematic review.
    Lancet Oncol. 2021;22:e7-e17.
    PubMed     Abstract available


  27. DUBSKY P, Pinker K, Cardoso F, Montagna G, et al
    Breast conservation and axillary management after primary systemic therapy in patients with early-stage breast cancer: the Lucerne toolbox.
    Lancet Oncol. 2021;22:e18-e28.
    PubMed     Abstract available


  28. TOI M, Imoto S, Ishida T, Ito Y, et al
    Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial.
    Lancet Oncol. 2021;22:74-84.
    PubMed     Abstract available


  29. DENT R, Rugo HS
    Most neoadjuvant chemotherapy for triple-negative breast cancer should include platinum.
    Lancet Oncol. 2021;22:27-28.
    PubMed    


  30. TAN AR, Im SA, Mattar A, Colomer R, et al
    Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study.
    Lancet Oncol. 2021;22:85-97.
    PubMed     Abstract available


  31. BARTSCH R, Minichsdorfer C, Kolberg-Liedtke C
    Results from the FeDeriCa trial: are we reducing the burden of breast cancer treatment?
    Lancet Oncol. 2021;22:5-6.
    PubMed    


    December 2020
  32. CROZIER JA, Pezzi TA, Hodge C, Janeva S, et al
    Addition of chemotherapy to local therapy in women aged 70 years or older with triple-negative breast cancer: a propensity-matched analysis.
    Lancet Oncol. 2020;21:1611-1619.
    PubMed     Abstract available


  33. CURIGLIANO G, Pravettoni G
    Use of chemotherapy in elderly patients with early-stage triple-negative breast cancer.
    Lancet Oncol. 2020;21:1543-1545.
    PubMed    


  34. BISWAS D, Ganeshalingam J, Wan JCM
    The future of liquid biopsy.
    Lancet Oncol. 2020;21:e550.
    PubMed    


    November 2020
  35. POORTMANS PM, Weltens C, Fortpied C, Kirkove C, et al
    Internal mammary and medial supraclavicular lymph node chain irradiation in stage I-III breast cancer (EORTC 22922/10925): 15-year results of a randomised, phase 3 trial.
    Lancet Oncol. 2020 Nov 2. pii: S1470-2045(20)30472.
    PubMed     Abstract available


  36. COLES CE, Haviland JS, Kirby AM
    Internal mammary node irradiation in breast cancer: does benefit outweigh risk?
    Lancet Oncol. 2020 Nov 2. pii: S1470-2045(20)30551.
    PubMed    


  37. KOPANS DB
    Recommendations for breast cancer screening.
    Lancet Oncol. 2020;21:e513.
    PubMed    


  38. YAFFE MJ, Gordon PB, Linver MN
    Recommendations for breast cancer screening.
    Lancet Oncol. 2020;21:e512.
    PubMed    


  39. TABAR L, Dean PB
    Recommendations for breast cancer screening.
    Lancet Oncol. 2020;21:e511.
    PubMed    


  40. DUFFY SW, Sasieni PD
    Mammography screening for breast cancer-the UK Age trial - Authors' reply.
    Lancet Oncol. 2020;21:e510.
    PubMed    


  41. DONZELLI A, Giudicatti G, Sghedoni D
    Mammography screening for breast cancer-the UK Age trial.
    Lancet Oncol. 2020;21:e509.
    PubMed    


  42. NAROD SA
    Mammography screening for breast cancer-the UK Age trial.
    Lancet Oncol. 2020;21:e508.
    PubMed    


  43. GERA R, Michell MJ, Mokbel K
    Mammography screening for breast cancer-the UK Age trial.
    Lancet Oncol. 2020;21:e507.
    PubMed    


  44. JATOI I
    Mammography screening for breast cancer-the UK Age trial.
    Lancet Oncol. 2020;21:e506.
    PubMed    


  45. AL-SHAMSI HO
    Mammography screening for breast cancer-the UK Age trial.
    Lancet Oncol. 2020;21:e505.
    PubMed    


  46. BELL KJL, Irwig L, Nickel B, Hersch J, et al
    Mammography screening for breast cancer-the UK Age trial.
    Lancet Oncol. 2020;21:e504.
    PubMed    


  47. MILLER AB
    Recommendations for breast cancer screening - Author's reply.
    Lancet Oncol. 2020;21:514.
    PubMed    


  48. PRAT A, Guarneri V, Pare L, Griguolo G, et al
    A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.
    Lancet Oncol. 2020;21:1455-1464.
    PubMed     Abstract available


  49. SMITH I, Robertson J, Kilburn L, Wilcox M, et al
    Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial.
    Lancet Oncol. 2020;21:1443-1454.
    PubMed     Abstract available


  50. HURVITZ SA
    HER2DX: a tool that might inform treatment choices for HER2-positive breast cancer.
    Lancet Oncol. 2020;21:1392-1393.
    PubMed    


  51. MUNOZ M, Prat A
    Implementing preoperative endocrine therapy in breast cancer.
    Lancet Oncol. 2020;21:1390-1392.
    PubMed    


  52. KAIDAR-PERSON O, Kuhn T, Poortmans P
    Residual disease after mastectomy - Authors' reply.
    Lancet Oncol. 2020;21:e501.
    PubMed    


  53. WU ZY, Han J, Eom JS, Ahn SH, et al
    Residual disease after mastectomy.
    Lancet Oncol. 2020;21:e500.
    PubMed    


  54. BUNDRED NJ, Dodwell D, Bundred JR, Cutress RI, et al
    Residual disease after mastectomy.
    Lancet Oncol. 2020;21:e499.
    PubMed    


    October 2020
  55. HSU A, Matera R, Dizon DS
    Stewart-Treves syndrome: a rapidly fatal complication of breast cancer treatment.
    Lancet Oncol. 2020;21:e495.
    PubMed    


  56. EMENS LA, Esteva FJ, Beresford M, Saura C, et al
    Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial.
    Lancet Oncol. 2020;21:1283-1295.
    PubMed     Abstract available


    September 2020
  57. TURNER NC, Kingston B, Kilburn LS, Kernaghan S, et al
    Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial.
    Lancet Oncol. 2020 Sep 10. pii: S1470-2045(20)30444.
    PubMed     Abstract available


  58. BOURLOND F, Lipsker D
    Multiple brown papules at the site of mastectomy for breast cancer.
    Lancet Oncol. 2020;21:e460.
    PubMed    


    August 2020
  59. TELLI ML
    BROCADE3: a challenge to the treatment paradigm in BRCA breast cancer?
    Lancet Oncol. 2020 Aug 27. pii: S1470-2045(20)30431.
    PubMed    


  60. DIERAS V, Han HS, Kaufman B, Wildiers H, et al
    Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet Oncol. 2020 Aug 27. pii: S1470-2045(20)30447.
    PubMed     Abstract available


  61. DUFFY SW, Vulkan D, Cuckle H, Parmar D, et al
    Effect of mammographic screening from age 40 years on breast cancer mortality (UK Age trial): final results of a randomised, controlled trial.
    Lancet Oncol. 2020 Aug 12. pii: S1470-2045(20)30398.
    PubMed     Abstract available


  62. MILLER AB
    Final results of the UK Age trial on breast cancer screening age.
    Lancet Oncol. 2020 Aug 12. pii: S1470-2045(20)30428.
    PubMed    


  63. DOMCHEK SM, Postel-Vinay S, Im SA, Park YH, et al
    Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study.
    Lancet Oncol. 2020 Aug 6. pii: S1470-2045(20)30324.
    PubMed     Abstract available


  64. WEBER WP, Morrow M, Boniface J, Pusic A, et al
    Knowledge gaps in oncoplastic breast surgery.
    Lancet Oncol. 2020;21:e375-e385.
    PubMed     Abstract available


  65. KAIDAR-PERSON O, Kuhn T, Poortmans P
    Should we worry about residual disease after mastectomy?
    Lancet Oncol. 2020;21:1011-1013.
    PubMed    


    July 2020
  66. MARINGE C, Spicer J, Morris M, Purushotham A, et al
    The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study.
    Lancet Oncol. 2020 Jul 20. pii: S1470-2045(20)30388.
    PubMed     Abstract available


  67. MALEKPOUR M, Widger J
    Radiation-induced angiosarcoma in a patient with breast cancer.
    Lancet Oncol. 2020;21:e369.
    PubMed    


    May 2020
  68. JONES RH, Casbard A, Carucci M, Foxley A, et al
    Fulvestrant plus capivasertib for metastatic breast cancer - Authors' reply.
    Lancet Oncol. 2020;21:e234.
    PubMed    


  69. LUDMIR EB, McCaw ZR, Kim DH, Tian L, et al
    Fulvestrant plus capivasertib for metastatic breast cancer.
    Lancet Oncol. 2020;21:e233.
    PubMed    


  70. DEKKER TJA
    Fulvestrant plus capivasertib for metastatic breast cancer.
    Lancet Oncol. 2020;21:e232.
    PubMed    


  71. BENSON JR
    Quality of life after breast-conserving surgery for women with non-low-risk ductal carcinoma in situ.
    Lancet Oncol. 2020;21:612-614.
    PubMed    


  72. KING MT, Link EK, Whelan TJ, Olivotto IA, et al
    Quality of life after breast-conserving therapy and adjuvant radiotherapy for non-low-risk ductal carcinoma in situ (BIG 3-07/TROG 07.01): 2-year results of a randomised, controlled, phase 3 trial.
    Lancet Oncol. 2020;21:685-698.
    PubMed     Abstract available


    April 2020
  73. BATTISTI NML, Ring A
    CDK4/6 inhibition in HER2-positive breast cancer.
    Lancet Oncol. 2020 Apr 27. pii: S1470-2045(20)30164.
    PubMed    


  74. TOLANEY SM, Wardley AM, Zambelli S, Hilton JF, et al
    Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial.
    Lancet Oncol. 2020 Apr 27. pii: S1470-2045(20)30112.
    PubMed     Abstract available


  75. THOMPSON AM
    Breast conservation therapy versus mastectomy for breast cancer.
    Lancet Oncol. 2020;21:493-494.
    PubMed    


  76. ROYCE TJ, Gupta GP, Marks LB
    Breast conservation therapy versus mastectomy for breast cancer.
    Lancet Oncol. 2020;21:492-493.
    PubMed    


    March 2020
  77. LAMBERTINI M, Vaz-Luis I
    Is HER2-positive metastatic breast cancer still an incurable disease?
    Lancet Oncol. 2020 Mar 12. pii: S1470-2045(20)30058.
    PubMed    


  78. SWAIN SM, Miles D, Kim SB, Im YH, et al
    Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.
    Lancet Oncol. 2020 Mar 12. pii: S1470-2045(19)30863.
    PubMed     Abstract available


  79. STIRRUPS R
    Pembrolizumab for triple-negative breast cancer.
    Lancet Oncol. 2020 Mar 5. pii: S1470-2045(20)30154.
    PubMed    


  80. GAO JJ, Cheng J, Beaver JA, Prowell TM, et al
    Ethnicity-based differences in breast cancer features and responsiveness to CDK4/6 inhibitors combined with endocrine therapy - Authors' reply.
    Lancet Oncol. 2020;21:e131.
    PubMed    


  81. PALA L, Conforti F, Goldhirsch A
    Ethnicity-based differences in breast cancer features and responsiveness to CDK4/6 inhibitors combined with endocrine therapy.
    Lancet Oncol. 2020;21:e130.
    PubMed    


  82. COLEMAN R, Zhou Y, Chan A
    Adjuvant denosumab in early breast cancer - Authors' reply.
    Lancet Oncol. 2020;21:e125.
    PubMed    


  83. FUSCO V, Campisi G, Bedogni A
    Adjuvant denosumab in early breast-cancer.
    Lancet Oncol. 2020;21:e124.
    PubMed    


  84. DE BOISSIEU P, Trenque T
    Adjuvant denosumab in early breast-cancer.
    Lancet Oncol. 2020;21:e123.
    PubMed    


  85. SCIMECA M, Bonfiglio R, Urbano N, Schillaci O, et al
    Adjuvant denosumab in early breast cancer.
    Lancet Oncol. 2020;21:e122.
    PubMed    


  86. PETERS N, Conroy M, O'Reilly S
    Adjuvant denosumab in early breast cancer.
    Lancet Oncol. 2020;21:e121.
    PubMed    


    February 2020
  87. JONES RH, Casbard A, Carucci M, Cox C, et al
    Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial.
    Lancet Oncol. 2020 Feb 5. pii: S1470-2045(19)30817.
    PubMed     Abstract available


  88. NASRAZADANI A, Brufsky AM
    Capivasertib inhibits a key pathway in metastatic breast cancer.
    Lancet Oncol. 2020 Feb 5. pii: S1470-2045(19)30857.
    PubMed    


    January 2020
  89. NUZZOLESE I, Montemurro F
    Attrition in metastatic breast cancer: a metric to be reported in randomised clinical trials?
    Lancet Oncol. 2020;21:21-24.
    PubMed    


    December 2019
  90. GOURD K
    San Antonio Breast Cancer Symposium 2019.
    Lancet Oncol. 2019 Dec 19. pii: S1470-2045(19)30830.
    PubMed    


  91. CURIGLIANO G, Loibl S
    CDK4/6 inhibitors in breast cancer: one more step towards reduced mortality.
    Lancet Oncol. 2019 Dec 16. pii: S1470-2045(19)30808.
    PubMed    


  92. GAO JJ, Cheng J, Bloomquist E, Sanchez J, et al
    CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
    Lancet Oncol. 2019 Dec 16. pii: S1470-2045(19)30804.
    PubMed     Abstract available


  93. CRISTOFANILLI M
    Time for a shift in molecular down staging in luminal breast cancer.
    Lancet Oncol. 2019 Dec 11. pii: S1470-2045(19)30806.
    PubMed    


  94. PRAT A, Saura C, Pascual T, Hernando C, et al
    Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial.
    Lancet Oncol. 2019 Dec 11. pii: S1470-2045(19)30786.
    PubMed     Abstract available


  95. COLEMAN R, Finkelstein DM, Barrios C, Martin M, et al
    Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial.
    Lancet Oncol. 2019 Dec 2. pii: S1470-2045(19)30687.
    PubMed     Abstract available


  96. PERRONE F, Gravina A
    Denosumab in early breast cancer: negative data and a call to action.
    Lancet Oncol. 2019 Dec 2. pii: S1470-2045(19)30717.
    PubMed    


    November 2019
  97. WOODWARD WA
    Building momentum for subsets of patients with advanced triple-negative breast cancer.
    Lancet Oncol. 2019 Nov 27. pii: S1470-2045(19)30737.
    PubMed    


  98. SCHMID P, Rugo HS, Adams S, Schneeweiss A, et al
    Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet Oncol. 2019 Nov 27. pii: S1470-2045(19)30689.
    PubMed     Abstract available


    October 2019
  99. PARK YH, Kim TY, Kim GM, Kang SY, et al
    Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 tr
    Lancet Oncol. 2019 Oct 24. pii: S1470-2045(19)30565.
    PubMed     Abstract available


  100. DAS M
    Promising radiotherapy classifier for early breast cancer.
    Lancet Oncol. 2019 Oct 24. pii: S1470-2045(19)30720.
    PubMed    


  101. ROBERT M, Turner N
    Endocrine-based therapy versus chemotherapy in advanced breast cancer.
    Lancet Oncol. 2019 Oct 24. pii: S1470-2045(19)30686.
    PubMed    


  102. STIRRUPS R
    Abemaciclib plus fulvestrant for breast cancer.
    Lancet Oncol. 2019 Oct 3. pii: S1470-2045(19)30629.
    PubMed    


    September 2019
  103. GOEL S, Tolaney SM
    CDK4/6 inhibitors in breast cancer: a role in triple-negative disease?
    Lancet Oncol. 2019 Sep 27. pii: S1470-2045(19)30627.
    PubMed    


  104. TAN AR, Wright GS, Thummala AR, Danso MA, et al
    Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial.
    Lancet Oncol. 2019 Sep 27. pii: S1470-2045(19)30616.
    PubMed     Abstract available


  105. GIULIANO M, Schettini F, Rognoni C, Milani M, et al
    Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
    Lancet Oncol. 2019 Sep 4. pii: S1470-2045(19)30420.
    PubMed     Abstract available


  106. NAROD SA
    MRI versus mammography for breast cancer screening in women with familial risk (FaMRIsc).
    Lancet Oncol. 2019;20:e465.
    PubMed    


  107. ZOLNIKOV TR, Chambers D
    Barriers to treatment for patients with breast cancer in Kenya.
    Lancet Oncol. 2019;20:1206-1207.
    PubMed    


    August 2019
  108. GOURD E
    Pyrotinib versus lapatinib in HER2-positive breast cancer.
    Lancet Oncol. 2019 Aug 30. pii: S1470-2045(19)30568.
    PubMed    


  109. JACKISCH C
    Overcoming endocrine resistance in neoadjuvant endocrine therapy for early breast cancer.
    Lancet Oncol. 2019 Aug 8. pii: S1470-2045(19)30500.
    PubMed    


  110. SAURA C, Hlauschek D, Oliveira M, Zardavas D, et al
    Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
    Lancet Oncol. 2019 Aug 8. pii: S1470-2045(19)30334.
    PubMed     Abstract available


    June 2019
  111. BANERJI U, van Herpen CML, Saura C, Thistlethwaite F, et al
    Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study.
    Lancet Oncol. 2019 Jun 27. pii: S1470-2045(19)30328.
    PubMed     Abstract available


  112. SAADATMAND S, Geuzinge HA, Rutgers EJT, Mann RM, et al
    MRI versus mammography for breast cancer screening in women with familial risk (FaMRIsc): a multicentre, randomised, controlled trial.
    Lancet Oncol. 2019 Jun 17. pii: S1470-2045(19)30275.
    PubMed     Abstract available


  113. KUHL CK
    Underdiagnosis is the main challenge in breast cancer screening.
    Lancet Oncol. 2019 Jun 17. pii: S1470-2045(19)30314.
    PubMed    


  114. BURKI TK
    Night shift work and breast cancer.
    Lancet Oncol. 2019 Jun 6. pii: S1470-2045(19)30383.
    PubMed    


  115. TERRY MB, Liao Y, Hopper JL, MacInnis RJ, et al
    Performance of BCRAT in high-risk patients with breast cancer - Authors' reply.
    Lancet Oncol. 2019;20:e286.
    PubMed    


  116. GAIL MH
    Performance of BCRAT in high-risk patients with breast cancer.
    Lancet Oncol. 2019;20:e285.
    PubMed    


    May 2019
  117. STIRRUPS R
    Alpelisib plus fulvestrant for PIK3CA-mutated breast cancer.
    Lancet Oncol. 2019 May 23. pii: S1470-2045(19)30372.
    PubMed    


  118. DAS M
    GM1 for taxane-induced neuropathy in breast cancer.
    Lancet Oncol. 2019 May 23. pii: S1470-2045(19)30373.
    PubMed    


  119. VARATHARAJAH R
    Breast cancer screening by visually impaired women.
    Lancet Oncol. 2019 May 10. pii: S1470-2045(19)30290.
    PubMed    


  120. HOFVIND S, Holen AS, Aase HS, Houssami N, et al
    Two-view digital breast tomosynthesis versus digital mammography in a population-based breast cancer screening programme (To-Be): a randomised, controlled trial.
    Lancet Oncol. 2019 May 8. pii: S1470-2045(19)30161.
    PubMed     Abstract available


  121. BRANDAO M, Debiasi M, de Azambuja E
    Denosumab in early-stage breast cancer.
    Lancet Oncol. 2019;20:e234-e235.
    PubMed    


  122. RODRIGUEZ EG, Aubry-Rozier B, Stoll D, Lamy O, et al
    Denosumab in early-stage breast cancer.
    Lancet Oncol. 2019;20:e233.
    PubMed    


  123. GNANT M, Pfeiler G, Frantal S
    Denosumab in early-stage breast cancer - Authors' reply.
    Lancet Oncol. 2019;20:236.
    PubMed    


    April 2019
  124. TAMURA K, Tsurutani J, Takahashi S, Iwata H, et al
    Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.
    Lancet Oncol. 2019 Apr 29. pii: S1470-2045(19)30097.
    PubMed     Abstract available


  125. WANDER SA, Spring LM, Bardia A
    Genetics to epigenetics: targeting histone deacetylases in hormone receptor-positive metastatic breast cancer.
    Lancet Oncol. 2019 Apr 26. pii: S1470-2045(19)30279.
    PubMed    


  126. JIANG Z, Li W, Hu X, Zhang Q, et al
    Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet Oncol. 2019 Apr 26. pii: S1470-2045(19)30164.
    PubMed     Abstract available


  127. BURKI TK
    Fulvestrant plus anastrozole for metastatic breast cancer.
    Lancet Oncol. 2019 Apr 4. pii: S1470-2045(19)30217.
    PubMed    


    March 2019
  128. DAS M
    Supplemental ultrasonography for breast cancer screening.
    Lancet Oncol. 2019 Mar 28. pii: S1470-2045(19)30211.
    PubMed    


  129. STIRRUPS R
    Neratinib and capecitabine for breast cancer brain metastases.
    Lancet Oncol. 2019 Mar 22. pii: S1470-2045(19)30184.
    PubMed    


  130. CHAE SY, Ahn SH, Kim SB, Han S, et al
    Diagnostic accuracy and safety of 16alpha-[(18)F]fluoro-17beta-oestradiol PET-CT for the assessment of oestrogen receptor status in recurrent or metastatic lesions in patients with breast cancer: a prospective cohort study.
    Lancet Oncol. 2019 Mar 4. pii: S1470-2045(18)30936.
    PubMed     Abstract available


  131. MANKOFF DA, Clark AS
    PET oestrogen receptor imaging: ready for the clinic?
    Lancet Oncol. 2019 Mar 4. pii: S1470-2045(19)30038.
    PubMed    


  132. ESTEVA FJ, Hubbard-Lucey VM, Tang J, Pusztai L, et al
    Immunotherapy and targeted therapy combinations in metastatic breast cancer.
    Lancet Oncol. 2019;20:e175-e186.
    PubMed     Abstract available


  133. CATANIA G, Ghirotto L, Leo SD, Timmins F, et al
    What a picture can tell you about surviving breast cancer.
    Lancet Oncol. 2019;20:335.
    PubMed    


    February 2019
  134. STIRRUPS R
    Sacituzumab govitecan-hziy for triple-negative breast cancer.
    Lancet Oncol. 2019 Feb 28. pii: S1470-2045(19)30074.
    PubMed    


  135. TERRY MB, Liao Y, Whittemore AS, Leoce N, et al
    10-year performance of four models of breast cancer risk: a validation study.
    Lancet Oncol. 2019 Feb 21. pii: S1470-2045(18)30902.
    PubMed     Abstract available


  136. GARCIA-CLOSAS M, Chatterjee N
    Assessment of breast cancer risk: which tools to use?
    Lancet Oncol. 2019 Feb 21. pii: S1470-2045(19)30071.
    PubMed    


  137. GNANT M, Pfeiler G, Steger GG, Egle D, et al
    Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet Oncol. 2019 Feb 19. pii: S1470-2045(18)30862.
    PubMed     Abstract available


  138. LIPPMAN M
    Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer.
    Lancet Oncol. 2019 Feb 19. pii: S1470-2045(18)30913.
    PubMed    


  139. PEOPLES GE
    Improving the outcomes of checkpoint inhibitors in breast cancer.
    Lancet Oncol. 2019 Feb 11. pii: S1470-2045(19)30068.
    PubMed    


  140. LOI S, Giobbie-Hurder A, Gombos A, Bachelot T, et al
    Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial.
    Lancet Oncol. 2019 Feb 11. pii: S1470-2045(18)30812.
    PubMed     Abstract available


    January 2019
  141. WANG SL, Fang H, Song YW, Wang WH, et al
    Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial.
    Lancet Oncol. 2019 Jan 30. pii: S1470-2045(18)30813.
    PubMed     Abstract available


  142. SAAD ED, Squifflet P, Burzykowski T, Quinaux E, et al
    Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis.
    Lancet Oncol. 2019 Jan 29. pii: S1470-2045(18)30750.
    PubMed     Abstract available


  143. AMIR E
    Endpoint selection in HER2-positive early breast cancer.
    Lancet Oncol. 2019 Jan 29. pii: S1470-2045(18)30779.
    PubMed    


  144. GOURD E
    Degarelix improves suppression of ovarian function.
    Lancet Oncol. 2019 Jan 11. pii: S1470-2045(19)30001.
    PubMed    


    December 2018
  145. BURKI TK
    T-DM1 for residual, invasive, HER2-positive breast cancer.
    Lancet Oncol. 2018 Dec 13. pii: S1470-2045(18)30918.
    PubMed    


    November 2018
  146. VAN RAMSHORST MS, van der Voort A, van Werkhoven ED, Mandjes IA, et al
    Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial.
    Lancet Oncol. 2018 Nov 6. pii: S1470-2045(18)30570.
    PubMed     Abstract available


    October 2018
  147. VELIKOVA G, Williams LJ, Willis S, Dixon JM, et al
    Quality of life after postmastectomy radiotherapy in patients with intermediate-risk breast cancer (SUPREMO): 2-year follow-up results of a randomised controlled trial.
    Lancet Oncol. 2018 Oct 15. pii: S1470-2045(18)30515.
    PubMed     Abstract available


  148. YAFFE MJ
    Towards improving accuracy, effectiveness, and efficiency in breast cancer screening.
    Lancet Oncol. 2018 Oct 12. pii: S1470-2045(18)30589.
    PubMed    


    September 2018
  149. GOURD E
    Lurbinectedin for BRCA-mutated advanced breast cancer.
    Lancet Oncol. 2018 Sep 27. pii: S1470-2045(18)30737.
    PubMed    


  150. STIRRUPS R
    Atezolizumab for metastatic triple-negative breast cancer.
    Lancet Oncol. 2018 Sep 20. pii: S1470-2045(18)30706.
    PubMed    


  151. KUERER HM
    More evidence for further minimisation of breast-cancer surgery.
    Lancet Oncol. 2018 Sep 5. pii: S1470-2045(18)30416.
    PubMed    


  152. GALIMBERTI V, Cole BF, Viale G, Veronesi P, et al
    Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial.
    Lancet Oncol. 2018 Sep 5. pii: S1470-2045(18)30380.
    PubMed     Abstract available


  153. PE M, Dorme L, Coens C, Basch E, et al
    Statistical analysis of patient-reported outcome data in randomised controlled trials of locally advanced and metastatic breast cancer: a systematic review.
    Lancet Oncol. 2018;19:e459-e469.
    PubMed     Abstract available


    August 2018
  154. GUNJUR A
    Talazoparib for BRCA-mutated advanced breast cancer.
    Lancet Oncol. 2018 Aug 23. pii: S1470-2045(18)30650.
    PubMed    


  155. GOURD E
    New triple-negative breast cancer risk genes identified.
    Lancet Oncol. 2018 Aug 16. pii: S1470-2045(18)30614.
    PubMed    


  156. DERLIN T, Hueper K
    CXCR4-targeted therapy in breast cancer.
    Lancet Oncol. 2018;19:e370.
    PubMed    


  157. NICHOLLS E
    Breast cancer in a Renaissance Book of the Dead.
    Lancet Oncol. 2018;19:1023-1024.
    PubMed    


  158. GOURD E
    Mammography deficiencies: the result of poor positioning.
    Lancet Oncol. 2018;19:e385.
    PubMed    


    July 2018
  159. MARTIN M
    The LILAC trial and the blooming of anticancer biosimilars.
    Lancet Oncol. 2018;19:861-863.
    PubMed    


    June 2018
  160. BURKI TK
    Variations in breast cancer treatment and outcomes.
    Lancet Oncol. 2018 Jun 14. pii: S1470-2045(18)30451.
    PubMed    


  161. VON MINCKWITZ G, Colleoni M, Kolberg HC, Morales S, et al
    Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial.
    Lancet Oncol. 2018 Jun 4. pii: S1470-2045(18)30241.
    PubMed     Abstract available


    May 2018
  162. MURTHY R, Borges VF, Conlin A, Chaves J, et al
    Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study.
    Lancet Oncol. 2018 May 24. pii: S1470-2045(18)30256.
    PubMed     Abstract available


  163. FOUKAKIS T
    Ribociclib in premenopausal women with advanced breast cancer.
    Lancet Oncol. 2018 May 24. pii: S1470-2045(18)30367.
    PubMed    


  164. TRIPATHY D, Im SA, Colleoni M, Franke F, et al
    Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.
    Lancet Oncol. 2018 May 24. pii: S1470-2045(18)30292.
    PubMed     Abstract available


  165. BURKI TK
    Responses to carboplatin in BRCA1/2-mutated breast cancer.
    Lancet Oncol. 2018 May 24. pii: S1470-2045(18)30407.
    PubMed    


  166. GOURD E
    Low uptake of tamoxifen to prevent breast cancer.
    Lancet Oncol. 2018 May 3. pii: S1470-2045(18)30344.
    PubMed    


    April 2018
  167. PERNAS S, Martin M, Kaufman PA, Gil-Martin M, et al
    Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial.
    Lancet Oncol. 2018 Apr 26. pii: S1470-2045(18)30147.
    PubMed     Abstract available


  168. SCHAFER R, Strnad V, Polgar C, Uter W, et al
    Quality-of-life results for accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation in early breast cancer after breast-conserving surgery (GEC-ESTRO): 5-year results of a randomised, phase 3 trial.
    Lancet Oncol. 2018 Apr 20. pii: S1470-2045(18)30195.
    PubMed     Abstract available


  169. ECCLES DM, Copson ER
    Genetic testing for young women with breast cancer - Authors' reply.
    Lancet Oncol. 2018;19:e183.
    PubMed    


  170. METCALFE K, Akbari MR, Narod SA
    Genetic testing for young women with breast cancer.
    Lancet Oncol. 2018;19:e182.
    PubMed    


    March 2018
  171. MCGALE P, Dodwell D, Taylor C, Gray R, et al
    Neoadjuvant chemotherapy for early breast cancer - Author's reply.
    Lancet Oncol. 2018;19:e130.
    PubMed    


  172. KRUG D, Loibl S
    Neoadjuvant chemotherapy for early breast cancer.
    Lancet Oncol. 2018;19:e129.
    PubMed    


  173. CHARALAMPOUDIS P, Karakatsanis A
    Neoadjuvant chemotherapy for early breast cancer.
    Lancet Oncol. 2018;19:e128.
    PubMed    


    February 2018
  174. CURIGLIANO G
    Addition of platinum salts to neoadjuvant chemotherapy in triple-negative breast cancer: a new standard of care?
    Lancet Oncol. 2018 Feb 28. pii: S1470-2045(18)30129.
    PubMed    


  175. LOIBL S, O'Shaughnessy J, Untch M, Sikov WM, et al
    Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
    Lancet Oncol. 2018 Feb 28. pii: S1470-2045(18)30111.
    PubMed     Abstract available


  176. DE PLACIDO S, Gallo C, De Laurentiis M, Bisagni G, et al
    Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.
    Lancet Oncol. 2018 Feb 23. pii: S1470-2045(18)30116.
    PubMed     Abstract available


  177. WILDIERS H, Tryfonidis K, Dal Lago L, Vuylsteke P, et al
    Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
    Lancet Oncol. 2018 Feb 9. pii: S1470-2045(18)30083.
    PubMed     Abstract available


  178. BIANUCCI R, Perciaccante A, Charlier P, Appenzeller O, et al
    Earliest evidence of malignant breast cancer in Renaissance paintings.
    Lancet Oncol. 2018;19:166-167.
    PubMed    


    January 2018
  179. FASCHING PA
    Breast cancer in young women: do BRCA1 or BRCA2 mutations matter?
    Lancet Oncol. 2018 Jan 11. pii: S1470-2045(18)30008.
    PubMed    


  180. COPSON ER, Maishman TC, Tapper WJ, Cutress RI, et al
    Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study.
    Lancet Oncol. 2018 Jan 11. pii: S1470-2045(17)30891.
    PubMed     Abstract available


  181. GIANNI L, Bisagni G, Colleoni M, Del Mastro L, et al
    Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study.
    Lancet Oncol. 2018 Jan 8. pii: S1470-2045(18)30001.
    PubMed     Abstract available


  182. PIVOT X, Cox DG
    A new era for treatment development in HER2-positive breast cancer.
    Lancet Oncol. 2018 Jan 8. pii: S1470-2045(18)30002.
    PubMed    


  183. MALAGA G, Cuba-Fuentes S, Romero-Albino Z
    Implementation of a community-based breast cancer management programme.
    Lancet Oncol. 2018;19:e3.
    PubMed    


  184. GLIGOROV J
    Early HER2-positive breast cancers: time for a new revolution?
    Lancet Oncol. 2018;19:12-13.
    PubMed    


  185. CHLEBOWSKI RT, Pan K
    Complexity of intermittent letrozole adjuvant therapy.
    Lancet Oncol. 2018;19:13-15.
    PubMed    


    December 2017
  186. BURKI TK
    Improved progression-free survival in metastatic breast cancer.
    Lancet Oncol. 2017 Dec 21. pii: S1470-2045(17)30952.
    PubMed    


  187. NELSON R
    San Antonio Breast Cancer Symposium 2017.
    Lancet Oncol. 2017 Dec 14. pii: S1470-2045(17)30930.
    PubMed    


  188. DERKS MGM, van de Velde CJH
    Neoadjuvant chemotherapy in breast cancer: more than just downsizing.
    Lancet Oncol. 2017 Dec 11. pii: S1470-2045(17)30914.
    PubMed    



  189. Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials.
    Lancet Oncol. 2017 Dec 11. pii: S1470-2045(17)30777.
    PubMed     Abstract available


  190. SALGADO R, Loi S
    Tumour infiltrating lymphocytes in breast cancer: increasing clinical relevance.
    Lancet Oncol. 2017 Dec 7. pii: S1470-2045(17)30905.
    PubMed    


  191. DENKERT C, von Minckwitz G, Darb-Esfahani S, Lederer B, et al
    Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
    Lancet Oncol. 2017 Dec 7. pii: S1470-2045(17)30904.
    PubMed     Abstract available


  192. DI LEO A, Johnston S, Lee KS, Ciruelos E, et al
    Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet Oncol. 2017 Dec 6. pii: S1470-2045(17)30688.
    PubMed     Abstract available


  193. HO AY, Hu ZI, Mehrara BJ, Wilkins EG, et al
    Radiotherapy in the setting of breast reconstruction: types, techniques, and timing.
    Lancet Oncol. 2017;18:e742-e753.
    PubMed     Abstract available


    November 2017
  194. HURVITZ SA, Martin M, Symmans WF, Jung KH, et al
    Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
    Lancet Oncol. 2017 Nov 23. pii: S1470-2045(17)30716.
    PubMed     Abstract available


  195. COLLEONI M, Luo W, Karlsson P, Chirgwin J, et al
    Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial.
    Lancet Oncol. 2017 Nov 17. pii: S1470-2045(17)30715.
    PubMed     Abstract available


  196. MARTIN M, Holmes FA, Ejlertsen B, Delaloge S, et al
    Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet Oncol. 2017 Nov 13. pii: S1470-2045(17)30717.
    PubMed     Abstract available


  197. CHAVEZ-MACGREGOR M, Mittendorf EA
    Extended adjuvant therapy in patients with HER2-positive breast cancer: some answers, even more questions.
    Lancet Oncol. 2017 Nov 13. pii: S1470-2045(17)30844.
    PubMed    


  198. GOURD E
    Thermography should not be used in breast cancer screening.
    Lancet Oncol. 2017 Nov 2. pii: S1470-2045(17)30833.
    PubMed    


    October 2017
  199. COSTA L, Ferreira AR
    Adjuvant zoledronic acid to treat breast cancer: not for all.
    Lancet Oncol. 2017 Oct 13. pii: S1470-2045(17)30695.
    PubMed    


  200. COLEMAN R, Hall A, Albanell J, Hanby A, et al
    Effect of MAF amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: a secondary analysis of the international, open-label, randomised, controlled, phase 3 AZURE (BIG 01/04) trial.
    Lancet Oncol. 2017 Oct 13. pii: S1470-2045(17)30603.
    PubMed     Abstract available


  201. GOURD E
    Insulin analog linked to breast cancer risk.
    Lancet Oncol. 2017 Oct 5. pii: S1470-2045(17)30772.
    PubMed    


  202. DUGGAN C, Dvaladze AL, Tsu V, Jeronimo J, et al
    Resource-stratified implementation of a community-based breast cancer management programme in Peru.
    Lancet Oncol. 2017;18:e607-e617.
    PubMed     Abstract available


  203. PINEROS M, Ramos W, Antoni S, Abriata G, et al
    Cancer patterns, trends, and transitions in Peru: a regional perspective.
    Lancet Oncol. 2017;18:e573-e586.
    PubMed     Abstract available


    September 2017
  204. GOURD E
    Pyrotinib shows activity in metastatic breast cancer.
    Lancet Oncol. 2017 Sep 21. pii: S1470-2045(17)30755.
    PubMed    


    August 2017
  205. KERR J, Anderson C, Lippman SM
    Physical activity, sedentary behaviour, diet, and cancer: an update and emerging new evidence.
    Lancet Oncol. 2017;18:e457-e471.
    PubMed     Abstract available


  206. LEVIS BE, Binkley PF, Shapiro CL
    Cardiotoxic effects of anthracycline-based therapy: what is the evidence and what are the potential harms?
    Lancet Oncol. 2017;18:e445-e456.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: